Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.36 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.36 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29760877 | 1.00 | ACHE (0.46) | ACHEERN1ALDH1A1SMN1; SMN2ENPP2 | |
| SCHEMBL8709932 | 0.89 | ACHE (0.52) | ACHEERN1ALDH1A1SMN1; SMN2ENPP2 | |
| SCHEMBL29953008 | 0.82 | TUBB4A (0.40) | ERN1ALDH1A1SMN1; SMN2ENPP2PTPN1 | |
| SCHEMBL26116441 | 0.80 | ACHE (0.43) | ACHEERN1ALDH1A1SMN1; SMN2ENPP2 | |
| SCHEMBL17027285 | 0.80 | ACHE (0.43) | ACHEERN1ALDH1A1SMN1; SMN2ENPP2 | |
| SCHEMBL30994812 | 0.80 | ACHE (0.43) | ACHEERN1ALDH1A1SMN1; SMN2ENPP2 | |
| SCHEMBL448143 | 0.79 | CA2 (0.43) | ACHEALDH1A1ORAI1ORAI2ORAI3 | |
| SCHEMBL27380292 | 0.77 | ABCG2 (0.35) | ENPP2ORAI1ORAI2ORAI3FFAR4 | |
| SCHEMBL13220750 | 0.77 | HSD17B10 (0.38) | ERN1ALDH1A1ENPP2ORAI1ORAI2 | |
| SCHEMBL677166 | 0.73 | ACHE (0.45) | ACHEERN1ALDH1A1ENPP2ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638438-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | Xinthera, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4613749-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2025-09-10 | — | — | EP | disclosed |
| EP-4612150-A1 | BRIDGED BICYCLIC HETEROCYCLOALKYL PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | Ventus Therapeutics U.S., Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-20250257077-A1 | BRIDGED BICYCLIC HETEROCYCLOALKYL PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | VENTUS THERAPEUTICS U.S., INC. | 2025-08-14 | — | — | US | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| US-20240279214-A1 | ALPHA4 BETA7 INEGRIN ANTAGONISTS AND USES THEREOF | XINTHERA, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2024138042-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | XINTHERA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024094185-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097629-A1 | BRIDGED BICYCLIC HETEROCYCLOALKYL PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-1301490-A2 | 5-SUBSTITUTED 2-ARYL-4-PYRIMIDINONES | NEUROGEN CORPORATION (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030018035-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002100838-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1255740-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-1233949-A2 | 5-SUBSTITUTED ARYLPYRIMIDINES | NEUROGEN CORPORATION (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020072521-A1 | 5-substituted arylpyrimidines | NEUROGEN CORPORATION | 2002-06-13 | — | — | US | disclosed |
| US-20020052387-A1 | 5-Substituted 2-aryl-4-pyrimidinones | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | disclosed |
| WO-2002006242-A2 | 5-SUBSTITUTED 2-ARYL-4-PYRIMIDINONES | NEUROGEN CORPORATION (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001068614-A2 | 5-SUBSTITUTED ARYLPYRIMIDINES | NEUROGEN CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001060806-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | ACHE 852/4885ERN1 2607/4885ALDH1A1 3601/4885 |
| US-20250257077-A1 | BRIDGED BICYCLIC HETEROCYCLOALKYL PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | ACHE 4840/4885ERN1 982/4885ALDH1A1 2362/4885 |
| US-20020072521-A1 | 5-substituted arylpyrimidines | HTR5A, CRHR1, HTR4 | ACHE 4678/4885ERN1 3151/4885ALDH1A1 1278/4885 |
| US-20020052387-A1 | 5-Substituted 2-aryl-4-pyrimidinones | CRHR1, CRHR2, HTR4 | ACHE 4787/4885ERN1 3197/4885ALDH1A1 1083/4885 |
| US-20240279214-A1 | ALPHA4 BETA7 INEGRIN ANTAGONISTS AND USES THEREOF | ITGB7, ITGB4, ITGA4 | ACHE 2902/4885ERN1 2773/4885ALDH1A1 1190/4885 |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | ACHE 4478/4885ERN1 668/4885ALDH1A1 2869/4885 |
| US-20030018035-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | ACHE 3719/4885ERN1 2452/4885ALDH1A1 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.